gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo

Meeting Abstract

  • corresponding author presenting/speaker Martin Michaelis - Klinikum d. J.W. Goethe-Universität, Frankfurt am Main, Deutschland
  • Iduna Fichtner - Max-Delbrück-Zentrum für Molekulare Medizin, Berlin
  • Wolfram Haider - Institut für Tierpathologie, Berlin
  • Florian Rothweiler - Klinikum d. J.W. Goethe-Universität, Frankfurt am Main
  • Jaroslav Cinatl - Klinikum d. J.W. Goethe-Universität, Frankfurt am Main
  • Andreas Mack - Gamma Knife Zentrum, Frankfurt am Main
  • Hans Wilhelm Doerr - Klinikum d. J.W. Goethe-Universität, Frankfurt am Main
  • Jindrich Cinatl jr. - Klinikum d. J.W. Goethe-Universität, Frankfurt am Main

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO454

The electronic version of this article is the complete one and can be found online at:

Published: March 20, 2006

© 2006 Michaelis et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



The proteasome inhibitor bortezomib (Velcade) was recently approved for the treatment of therapy-refractive multiple myeloma and is under investigation for numerous other types of cancer. A phase I clinical trial in paediatric patients resulted in tolerable toxicity. Since the emergence of chemoresistances represents one of the major drawbacks in cancer therapy, we here investigated the influence of bortezomib on multi-drug resistant human neuroblastoma cell lines characterised by P-glycoprotein expression and p53 mutation. Nanomolar concentrations of bortezomib inhibited the cell the cycle of and induced apoptosis in chemosensitive as well as in chemoresistant cell lines. In vivo growth of chemosensitive and chemoresistant neuroblastoma cell lines was inhibited to a similar extent. In addition, bortezomib inhibited vessel formation in neuroblastoma xenografts. These findings and the favourable toxicity profile of bortezomib in children make it reasonable to further pursue additional development of the drug for the treatment of neuroblastoma and other paediatric solid tumours.